Celastrol suppresses invasion of colon and pancreatic cancer cells through the downregulation of expression of CXCR4 chemokine receptor.
Although metastasis accounts for >90% of cancer-related deaths, no therapeutic that targets this process has yet been approved. Because the chemokine receptor CXCR4 is one of the targets closely linked with tumor metastasis, inhibitors of this receptor have the potential to abrogate metastasis. In the current report, we demonstrate that celastrol can downregulate the CXCR4 expression on breast cancer MCF-7 cells stably transfected with HER2, an oncogene known to induce the chemokine receptor. Downregulation of CXCR4 by the triterpenoid was not cell type-specific as downregulation occurred in colon cancer, squamous cell carcinoma, and pancreatic cancer cells. Decrease in CXCR4 expression was not due to proteolysis as neither proteasome inhibitors nor lysosomal stabilization had any effect. Quantitative reverse transcription polymerase chain reaction analysis revealed that downregulation of CXCR4 messenger RNA (mRNA) by celastrol occurred at the translational level. Chromatin immunoprecipitation analysis revealed regulation at the transcriptional level as well. Abrogation of the chemokine receptor by celastrol or by gene-silencing was accompanied by suppression of invasiveness of colon cancer cells induced by CXCL12, the ligand for CXCR4. This effect was not cell type-specific as celastrol also abolished invasiveness of pancreatic tumor cells, and this effect again correlated with the disappearance of both the CXCR4 mRNA and CXCR4 protein. Other triterpenes, such as withaferin A and gedunin, which are known to inhibit Hsp90, did not downregulate CXCR4 expression, indicating that the effects were specific to celastrol. Overall, these results show that celastrol has potential in suppressing invasion and metastasis of cancer cells by down-modulation of CXCR4 expression.
Yadav
Vivek R
VR
Cytokine Research Laboratory, Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Sung
Bokyung
B
Prasad
Sahdeo
S
Kannappan
Ramaswamy
R
Cho
Sung-Gook
SG
Liu
Mingyao
M
Chaturvedi
Madan M
MM
Aggarwal
Bharat B
BB
D001943:Breast Neoplasms / Q000235:genetics / Q000473:pathology; D045744:Cell Line, Tumor; D054377:Chemokine CXCL12 / Q000494:pharmacology; D003110:Colonic Neoplasms / Q000235:genetics / Q000473:pathology*; D015536:Down-Regulation / Q000187:drug effects*; D004354:Drug Screening Assays, Antitumor; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D018841:HSP90 Heat-Shock Proteins / Q000037:antagonists & inhibitors / Q000378:metabolism; D006801:Humans; D016328:NF-kappa B / Q000378:metabolism; D009361:Neoplasm Invasiveness; D009928:Organ Specificity / Q000187:drug effects; D010190:Pancreatic Neoplasms / Q000235:genetics / Q000473:pathology*; D053978:Pentacyclic Triterpenes; D011499:Protein Processing, Post-Translational / Q000187:drug effects; D019718:Receptors, CXCR4 / Q000235:genetics* / Q000378:metabolism; D014315:Triterpenes / Q000737:chemistry / Q000494:pharmacology*; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology
C527276:CXCR4 protein, human; D054377:Chemokine CXCL12; D018841:HSP90 Heat-Shock Proteins; D016328:NF-kappa B; D053978:Pentacyclic Triterpenes; D019718:Receptors, CXCR4; D014315:Triterpenes; D014409:Tumor Necrosis Factor-alpha; C050414:celastrol
Angew Chem Int Ed Engl. 2009;48(32):5853-5
19585625
Cancer Res. 2002 Dec 15;62(24):7203-6
12499259
Clin Exp Metastasis. 2005;22(1):39-46
16132577
Cancer Res. 2009 Oct 15;69(20):7905-10
19826039
J Biol Chem. 2009 Dec 18;284(51):35381-9
19858214
Cell Stem Cell. 2008 Apr 10;2(4):333-44
18397753
Cancer Res. 2002 Mar 15;62(6):1832-7
11912162
Cancer Res. 2003 Jul 1;63(13):3833-9
12839981
Ann Surg Oncol. 2009 Sep;16(9):2645-53
19588204
Planta Med. 2004 Feb;70(2):93-103
14994184
Nature. 2000 Sep 14;407(6801):249-57
11001068
Blood. 2007 Apr 1;109(7):2727-35
17110449
J Biol Chem. 2003 Jun 13;278(24):21631-8
12690099
J Exp Med. 1993 May 1;177(5):1391-8
8478614
J Biol Chem. 2007 Dec 21;282(51):36971-9
17947233
Dev Cell. 2003 Nov;5(5):709-22
14602072
Cancer Res. 2010 Mar 1;70(5):1951-9
20160026
Cancer Res. 2004 Nov 15;64(22):8420-7
15548713
Cancer Res. 2005 Nov 1;65(21):9891-8
16267013
Biochem Pharmacol. 2006 Nov 15;72(10):1311-21
16984800
Cancer Res. 2006 May 1;66(9):4758-65
16651429
Cancer Cell. 2004 Nov;6(5):459-69
15542430
Cell. 2008 Sep 5;134(5):769-81
18775310
J Biol Chem. 2010 Feb 5;285(6):4224-4231
19996313
Blood. 2008 Jun 15;111(12):5654-62
18305216
J Leukoc Biol. 2006 Aug;80(2):309-19
16769766
Cancer Cell. 2009 Mar 3;15(3):220-31
19249680
Int J Cancer. 2007 Nov 15;121(10):2119-24
17849476
J Surg Res. 2007 Jul;141(1):53-9
17574038
J Biol Chem. 2004 Dec 31;279(53):56053-60
15509580
Cancer Cell. 2006 Oct;10(4):321-30
17010675
Cancer Res. 2005 Nov 15;65(22):10355-62
16288025
J Cell Physiol. 2006 Dec;209(3):645-52
17001676
Carcinogenesis. 2007 Feb;28(2):267-79
16840440
Biosci Biotechnol Biochem. 2003 Sep;67(9):1883-7
14519971
Nature. 2001 Mar 1;410(6824):50-6
11242036
Bioorg Med Chem Lett. 1998 Dec 15;8(24):3659-64
9934491
Biochem Biophys Res Commun. 2010 Apr 9;394(3):439-42
20226165
Ann N Y Acad Sci. 2004 Dec;1030:162-9
15659794
J Biol Chem. 2001 Dec 7;276(49):45509-12
11641392
Mol Cell. 2003 Dec;12(6):1577-89
14690609
Mol Cancer Ther. 2009 Aug;8(8):2339-47
19671767